Zacks Investment Research upgraded shares of Stemline Therapeutics (NASDAQ:STML) from a sell rating to a hold rating in a research note published on Friday.

According to Zacks, “Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. “

A number of other brokerages have also recently issued reports on STML. Cowen reissued a buy rating on shares of Stemline Therapeutics in a research note on Tuesday, October 31st. HC Wainwright reaffirmed a buy rating and set a $34.00 target price on shares of Stemline Therapeutics in a research note on Tuesday, September 12th. BidaskClub cut shares of Stemline Therapeutics from a buy rating to a hold rating in a research note on Thursday, December 7th. Finally, ValuEngine raised shares of Stemline Therapeutics from a sell rating to a hold rating in a research note on Sunday, December 31st. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $33.75.

Stemline Therapeutics (NASDAQ STML) opened at $14.65 on Friday. The stock has a market cap of $384.36, a P/E ratio of -5.70 and a beta of -0.02. Stemline Therapeutics has a one year low of $5.50 and a one year high of $16.20.

In other Stemline Therapeutics news, COO Kenneth Hoberman sold 11,943 shares of the business’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $14.18, for a total transaction of $169,351.74. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 16.70% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. C WorldWide Group Holding A S bought a new stake in shares of Stemline Therapeutics during the third quarter worth $1,776,000. Northern Trust Corp grew its stake in shares of Stemline Therapeutics by 18.0% during the second quarter. Northern Trust Corp now owns 274,824 shares of the biopharmaceutical company’s stock worth $2,529,000 after buying an additional 41,898 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Stemline Therapeutics by 74.9% during the second quarter. Dimensional Fund Advisors LP now owns 120,477 shares of the biopharmaceutical company’s stock worth $1,108,000 after buying an additional 51,578 shares during the last quarter. Lyon Street Capital LLC grew its stake in shares of Stemline Therapeutics by 331.1% during the third quarter. Lyon Street Capital LLC now owns 541,462 shares of the biopharmaceutical company’s stock worth $6,010,000 after buying an additional 415,867 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Stemline Therapeutics by 4.7% during the second quarter. Vanguard Group Inc. now owns 863,768 shares of the biopharmaceutical company’s stock worth $7,946,000 after buying an additional 38,615 shares during the last quarter. 50.24% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/stemline-therapeutics-stml-upgraded-by-zacks-investment-research-to-hold/1797487.html.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.